Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01208129 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails
A Phase 3 study, sponsored by Promius Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 458
- Enrollment target
NCT01208129 is a Phase 3 study that was terminated before completion, run by Promius Pharma. The registered enrollment target is 458 participants.
The verdict
NCT01208129, a Phase 3 study, was terminated before completion, sponsored by Promius Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 458 participants
- Enrollment target
Study Summary
The objectives of this study are to assess the safety of NAB001 for topical treatment of mild to moderate distal onychomycosis of the toenails over 52 weeks and to compare the efficacy of NAB001 to vehicle alone at the end of the study (Week 56) after treating for 52 weeks.
Interventions
- DRUG Placebo control
- DRUG NAB001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 458 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01208129
The ClinicalTrials.gov registry entry for NCT01208129 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 458 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Promius Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo control is the first listed.
NCT01208129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01208129 about?
NCT01208129 is a clinical study titled "Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails". The objectives of this study are to assess the safety of NAB001 for topical treatment of mild to moderate distal onychomycosis of the toenails over 52 weeks and to compare the efficacy of NAB001 to vehicle alone at the end of the study (Week 56) after treating for 52 weeks.
What is the current status of trial NCT01208129?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 458 participants. The study started on 2010-09. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01208129?
The interventions under investigation include: Placebo control (DRUG), NAB001 (DRUG).
Who is sponsoring clinical trial NCT01208129?
This trial is sponsored by Promius Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.